Clinical Trials Logo

Adult Disease clinical trials

View clinical trials related to Adult Disease.

Filter by:

NCT ID: NCT06403436 Recruiting - Cancer Clinical Trials

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors

TT-CSP-001
Start date: November 7, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety and therapeutic effect of TT125-802 (single agent) in subjects with advanced solid tumors.

NCT ID: NCT06196892 Not yet recruiting - Alcohol Drinking Clinical Trials

Probiotics Improve Drinkers' Gut Microbiota

Start date: April 20, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to understand the effects of the probiotic Bifidobacterium breve BBr60 on the gut health of people who drink alcohol regularly. We want to find out if this probiotic can help improve the health of the digestive system in those who consume alcohol. The main questions we aim to answer are: Does Bifidobacterium breve BBr60 positively change the composition of gut bacteria in alcohol consumers? Participants in this study will: Be randomly assigned to one of two groups. One group will receive the probiotic Bifidobacterium breve BBr60, and the other group will receive a placebo (a substance with no active therapeutic effect). Take their assigned treatment for a specified period, as directed by the study protocol. Undergo regular health checks and provide feceal samples for analysis to see how their gut bacteria might have changed during the study. This study is important because it explores whether a specific type of probiotic can help protect or improve gut health in people who drink alcohol, potentially offering a new way to support digestive health.

NCT ID: NCT06007092 Recruiting - Clinical trials for Head and Neck Carcinoma

Therapeutic Vaccine in Patients With Human Papillomavirus HPV-positive Oropharyngeal Cancer

HPVDCVax
Start date: July 31, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a multicentric double-blind placebo-controlled dose escalation trial of a CD40HVac vaccine (humanized anti-CD40 mAb fused to HPV16 E6/E7 oncoproteins) adjuvanted with poly-ICLC (Hiltonol) in patients with HPV16 oropharyngeal carcinoma with no evidence of residual or recurrent disease after surgery and/or radiochemotherapy. The primary objective is to determine the recommended phase 2 dose (RP2D) of a poly-ICLC(Hiltonol)-adjuvanted CD40HVac vaccine according to the safety and the capacity to elicit immune responses of different doses Two dose levels of poly-ICLC-adjuvanted CD40.HVac will be explored - 1st dose level: CD40.HVac 1.0 mg, with 1.0 mg poly-ICLC - 2nd dose level: CD40.HVac 3.0 mg, with 1.0 mg poly-ICLC The safety data will be reviewed by an IDSMB that will give recommendations.

NCT ID: NCT05817734 Recruiting - Adult Disease Clinical Trials

Human Phenotype Project Study Protocol

Start date: October 1, 2018
Phase:
Study type: Observational

This is a prospective study aimed at recruiting 30,000 individuals, aged 40-70 years old, and following them longitudinally for 25 years with repeated measurements. The basic follow-up frame will include a visit to the Clinical Test Center (CTC) every two years and a phone interview every other year (on uneven years). Sample collection and biobanking will be performed every two years and online questionnaires will be filled out on an annual basis. The primary goals are to study the variation observed across different individuals in disease susceptibility, clinical phenotypes, and therapeutic responses. The study aims at studying the complex interplay and relative contribution of different omics, physiological characteristics and lifestyle on disease pathogenesis and progression and to evaluate how these effects are mediated.

NCT ID: NCT05641324 Terminated - Multiple Myeloma Clinical Trials

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Start date: February 10, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of ANV419 monotherapy followed by ANV419 in combination with lenalidomide plus low-dose dexamethasone or ANV419 in combination with daratumumab.

NCT ID: NCT05578872 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).

Start date: December 16, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of ANV419 monotherapy or the combination of ANV419 with anti-PD1 antibody or with anti-CTLA4 antibody in adult participants with advanced (unresectable or metastatic) cutaneous melanoma.

NCT ID: NCT04958499 Completed - Adult Disease Clinical Trials

Effectiveness of Bio-Healthy Park on Adult

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

Bio-healthy parks are an alternative for practicing physical activity outdoors and free of charge. However, there is no research that analyzes the effect of a planned training program in these parks. There are two types of parks under development, with and without externally added resistance. Therefore, general objective of this project are to evaluate the effect of 8 weeks of targeted training in bio-healthy parks on body composition, bone mineral density, blood pressure, strength, functional capacity, sarcopenia, sagittal disposition of the spine, quality of life, life satisfaction and Mediterranean diet adherence in adults and older adults. The present project will be developed through a randomized controlled trial, with 1 experimental and 1 control group, with pre-test and post-test, with intra-group and inter-group analysis for each of the dependent variables of the study. It will be measure body composition, bone mineral density, blood pressure, upper limb strength, lower limb strength, functional capacity, sarcopenia, sagittal disposition of the spine, Health-related quality of life, satisfaction with life and Mediterranean diet adherence. Experimental group will receive the exercise program on bio-healthy park machine with a frequency of 2 sessions per week of 55 minutes for 8 weeks. The control group will not perform any intervention program following their usual activity.

NCT ID: NCT04855929 Recruiting - Lung Cancer Clinical Trials

A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients With Advanced Cancer.

ANV419-001
Start date: May 25, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety and efficacy of ANV419 (single agent) and in combination with ipilimumab in patients with relapsed/refractory advanced solid tumors.

NCT ID: NCT04819035 Completed - Sepsis Clinical Trials

Sepsis Post Market Clinical Utility Simple Endpoint Study - Indiana University Hospital

Start date: June 17, 2021
Phase:
Study type: Observational

The purpose of this study is to demonstrate that addition of the Monocyte Width Distribution (MDW) parameter to current standard of care improves a clinician's ability to recognize sepsis in the Emergency Department, resulting in earlier decision to administer antibiotics from time of ED presentation for sepsis patients (simulated primary endpoint), with concomitant reductions in length of stay and in-hospital mortality for those patients (secondary endpoints).

NCT ID: NCT04804306 Completed - Sepsis Clinical Trials

Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC

Start date: September 5, 2021
Phase:
Study type: Observational

The purpose of this study is to demonstrate that addition of the Monocyte Width Distribution (MDW) parameter to current standard of care improves a clinician's ability to recognize sepsis in the Emergency Department, resulting in earlier decision to administer antibiotics from time of ED presentation for sepsis patients (simulated primary endpoint), with concomitant reductions in length of stay and in-hospital mortality for those patients (secondary endpoints).